Pharmacological correction of hypothermic P50 shift does not alter outcome from focal cerebral ischemia in rats

Mark S. Wainwright, Huaxin Sheng, Yukie Sato, G. Burkhard Mackensen, Robert P. Steffen, Robert D. Pearlstein, David S. Warner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Hypothermia decreases the arterial Po2 at which hemoglobin is 50% saturated (P50), increasing hemoglobin O2-binding affinity. We used RSR13, a synthetic allosteric modifier of hemoglobin that increases P50, to study the role of altered hemoglobin O2-binding affinity in mild hypothermic neuroprotection. RSR13 (150 mg/kg iv) restored P50 to normothermic values. Rats underwent 70 min of middle cerebral artery occlusion (MCAO) at 30.0, 34.0, or 37.5°C with hemoglobin saturation held at 98-100%. The 34.0°C group received RSR13 or vehicle before ischemia. After 7 days of recovery, infarct volumes were reduced in all hypothermic groups, without evidence of a detrimental effect on infarct size or neurological score as a result of P50 correction. To examine for a beneficial effect of P50 correction, ischemia duration was increased to 120 min in rats maintained at 34.0°C. Correction of P50 by RSR13 did not alter cerebral infarct sizes or neurological scores. The decrease in P50, caused by mild hypothermia, could not be associated with infarct size or neurological deficit resulting from ischemic brain hypoxia in rats.

Original languageEnglish (US)
Pages (from-to)H1863-H1870
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Issue number5 51-5
StatePublished - 2002


  • Allosteric modification
  • Brain
  • Hypothermia
  • RSR13

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Pharmacological correction of hypothermic P50 shift does not alter outcome from focal cerebral ischemia in rats'. Together they form a unique fingerprint.

Cite this